Clinical Trial Update: Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1 [Phase 1]

View source ↗

Summary

A Phase 1 safety, tolerability, and pharmacokinetic study evaluating single doses of ABT-450 with and without ritonavir in adults with Hepatitis C genotype 1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-450 (atazanavir)
• Ritonavir (Ritonavir)

Snippet

Sponsor: AbbVie | Conditions: HCV Infection | Phase 1 | Status: COMPLETED